These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 20068111)

  • 21. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
    Cairo MS; Davenport V; Bessmertny O; Goldman SC; Berg SL; Kreissman SG; Laver J; Shen V; Secola R; van de Ven C; Reaman GH
    Br J Haematol; 2005 Jan; 128(1):49-58. PubMed ID: 15606549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunological consequences of interleukin 12 administration after autologous stem cell transplantation.
    Pelloso D; Cyran K; Timmons L; Williams BT; Robertson MJ
    Clin Cancer Res; 2004 Mar; 10(6):1935-42. PubMed ID: 15041709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors.
    Margolin K; Morishima C; Velcheti V; Miller JS; Lee SM; Silk AW; Holtan SG; Lacroix AM; Fling SP; Kaiser JC; Egan JO; Jones M; Rhode PR; Rock AD; Cheever MA; Wong HC; Ernstoff MS
    Clin Cancer Res; 2018 Nov; 24(22):5552-5561. PubMed ID: 30045932
    [No Abstract]   [Full Text] [Related]  

  • 24. Phase 1 trial of recombinant human interleukin-1 beta (rhIL-1 beta), carboplatin, and etoposide in patients with solid cancers: Southwest Oncology, Group Study 8940.
    Rinehart J; Hersh E; Issell B; Triozzi P; Buhles W; Neidhart J
    Cancer Invest; 1997; 15(5):403-10. PubMed ID: 9316621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A dose-escalation and pharmacokinetic study of subcutaneously administered recombinant human interleukin 12 and its biological effects in Japanese patients with advanced malignancies.
    Ohno R; Yamaguchi Y; Toge T; Kinouchi T; Kotake T; Shibata M; Kiyohara Y; Ikeda S; Fukui I; Gohchi A; Sugiyama Y; Saji S; Hazama S; Oka M; Ohnishi K; Ohhashi Y; Tsukagoshi S; Taguchi T
    Clin Cancer Res; 2000 Jul; 6(7):2661-9. PubMed ID: 10914707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant human IL-7 administration in mice affects colony-forming units-spleen and lymphoid precursor cell localization and accelerates engraftment of bone marrow transplants.
    Boerman OC; Gregorio TA; Grzegorzewski KJ; Faltynek CR; Kenny JJ; Wiltrout RH; Komschlies KL
    J Leukoc Biol; 1995 Aug; 58(2):151-8. PubMed ID: 7643010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IL-7 stimulates T cell renewal without increasing viral replication in simian immunodeficiency virus-infected macaques.
    Nugeyre MT; Monceaux V; Beq S; Cumont MC; Ho Tsong Fang R; Chêne L; Morre M; Barré-Sinoussi F; Hurtrel B; Israël N
    J Immunol; 2003 Oct; 171(8):4447-53. PubMed ID: 14530372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exogenous interleukin 7 as a proliferative stimulant of early precursor B cells in mouse bone marrow: efficacy of IL-7 injection, IL-7 infusion and IL-7-anti-IL-7 antibody complexes.
    Valenzona HO; Dhanoa S; Finkelman FD; Osmond DG
    Cytokine; 1998 Jun; 10(6):404-12. PubMed ID: 9632525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid modifications of peripheral T-cell subsets that express CD127 in macaques treated with recombinant IL-7.
    Dereuddre-Bosquet N; Vaslin B; Delache B; Brochard P; Clayette P; Aubenque C; Morre M; Assouline B; Le Grand R
    J Med Primatol; 2007 Aug; 36(4-5):228-37. PubMed ID: 17669211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 1 trial of subcutaneous IL-6 in patients with refractory cancer: clinical and biologic effects.
    Olencki T; Finke J; Tubbs R; Elson P; McLain D; Herzog P; Budd GT; Gunn H; Bukowski RM
    J Immunother; 2000; 23(5):549-56. PubMed ID: 11001548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma.
    Davis ID; Skrumsager BK; Cebon J; Nicholaou T; Barlow JW; Moller NP; Skak K; Lundsgaard D; Frederiksen KS; Thygesen P; McArthur GA
    Clin Cancer Res; 2007 Jun; 13(12):3630-6. PubMed ID: 17575227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.
    Naing A; Papadopoulos KP; Autio KA; Ott PA; Patel MR; Wong DJ; Falchook GS; Pant S; Whiteside M; Rasco DR; Mumm JB; Chan IH; Bendell JC; Bauer TM; Colen RR; Hong DS; Van Vlasselaer P; Tannir NM; Oft M; Infante JR
    J Clin Oncol; 2016 Oct; 34(29):3562-3569. PubMed ID: 27528724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer.
    Robertson MJ; Cameron C; Atkins MB; Gordon MS; Lotze MT; Sherman ML; Ritz J
    Clin Cancer Res; 1999 Jan; 5(1):9-16. PubMed ID: 9918197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer.
    Veldhuis GJ; Willemse PH; Sleijfer DT; van der Graaf WT; Groen HJ; Limburg PC; Mulder NH; de Vries EG
    J Clin Oncol; 1995 Oct; 13(10):2585-93. PubMed ID: 7595711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant glycosylated human interleukin-6 accelerates peripheral blood platelet count recovery in radiation-induced bone marrow depression in baboons.
    Herodin F; Mestries JC; Janodet D; Martin S; Mathieu J; Gascon MP; Pernin MO; Ythier A
    Blood; 1992 Aug; 80(3):688-95. PubMed ID: 1638022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hematologic and immunologic evaluation of recombinant human interleukin-6 in patients with advanced malignant disease: evidence for monocyte activation.
    Keever-Taylor CA; Witt PL; Truitt RL; Ramanujam S; Borden EC; Ritch PS
    J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):231-43. PubMed ID: 8811498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biologic activity of interleukin 1 (IL-1) alpha in patients with refractory malignancies.
    Rosenthal MA; Dennis D; Liebes L; Furmanski P; Caron D; Garrison L; Wiprovnick J; Peace D; Oratz R; Speyer J; Chachoua A
    J Immunother; 1998 Sep; 21(5):371-8. PubMed ID: 9789199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses.
    Rook AH; Wood GS; Yoo EK; Elenitsas R; Kao DM; Sherman ML; Witmer WK; Rockwell KA; Shane RB; Lessin SR; Vonderheid EC
    Blood; 1999 Aug; 94(3):902-8. PubMed ID: 10419880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. hIL-7-hyFc, A Long-Acting IL-7, Increased Absolute Lymphocyte Count in Healthy Subjects.
    Lee SW; Choi D; Heo M; Shin EC; Park SH; Kim SJ; Oh YK; Lee BH; Yang SH; Sung YC; Lee H
    Clin Transl Sci; 2020 Nov; 13(6):1161-1169. PubMed ID: 32339447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10.
    Santin AD; Bellone S; Palmieri M; Bossini B; Dunn D; Roman JJ; Pecorelli S; Cannon M; Parham GP
    Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1345-55. PubMed ID: 12459356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.